---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-24-000124"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:06:28.991410+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pacira names Lauren Riker interim CFO; Reinhart departs Sept 30

## Summary
- CFO Charles Reinhart departs Sept 30, 2024; will serve as consultant for 9 months.
- Lauren Riker, SVP of Finance, appointed interim CFO effective Oct 1, 2024.
- Riker's base salary unchanged at $374,700; bonus target 50%; receives one-time $75k bonus.
- Riker to serve as interim CFO until permanent successor identified.
- No changes to existing employment agreement or other compensation terms.

## SEC filing metadata
- accession: 0001396814-24-000124
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000124/0001396814-24-000124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000124/pcrx-20240926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-24-000124
- JSON: https://secwatch.observer/filing/0001396814-24-000124.json
- Plain text: https://secwatch.observer/filing/0001396814-24-000124.txt

## Key facts
- Executive change
  Charles A. Reinhart, III departed as Chief Financial Officer at Pacira BioSciences, Inc..
  - Action: depart
  - Role: Chief Financial Officer
  source text: Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he would depart the Company effective September 30, 2024, and will continue to serve as consultant to the Company for a period of nine months thereafter.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000124/0001396814-24-000124-index.htm
- Executive change
  Lauren Riker was appointed as interim Chief Financial Officer at Pacira BioSciences, Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: On September 26, 2024, the Board of Directors of the Company (the “Board”) appointed Lauren Riker, the Company’s current Senior Vice President of Finance and principal accounting officer, to also serve as interim Chief Financial Officer of the Company (including as principal financial officer and continuing as principal accounting officer for Securities and Exchange Commission reporting purposes), effective October 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000124/0001396814-24-000124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.